Why carry out this study?

Chronic back pain is a very prevalent disease that presents a significant social and economic burden and is continually growing due to lifestyle habits and the progressive aging of the population.

Regenerative medicine offers biological therapies utilizing blood derivatives, such as plasma rich in growth factors (PRGF) as a solution for treating chronic back pain. These therapies are minimally invasive and autologous, representing an innovative biological approach to pain management.

The purpose of the present study was to retrospectively examine patient records and determine whether the improvement observed in the patients treated with PRGF was sustained over time.

What was learned from the study?

Previous studies have shown that intradiscal and epidural infiltration of PRGF significantly reduces chronic back pain and physical disability for at least 6 months.

The present study supports the findings of the previous prospective study and provides additional data on long-term effects, as the improvement in all scales evaluated was maintained in the majority of patients (85.2%) over a mean follow-up period of 24 months.